A Redox‐Triggered Bispecific Supramolecular Nanomedicine Based on Peptide Self‐Assembly for High‐Efficacy and Low‐Toxic Cancer Therapy

2019 ◽  
Vol 30 (4) ◽  
pp. 1904969 ◽  
Author(s):  
Da‐Song Yang ◽  
Yin‐He Yang ◽  
Yunjiang Zhou ◽  
Li‐Li Yu ◽  
Rui‐Han Wang ◽  
...  
Keyword(s):  
Cancer Therapy ◽  
Self Assembly ◽  
High Efficacy ◽  
Low Toxic

Dual Intratumoral Redox/Enzyme-Responsive NO-Releasing Nanomedicine for the Specific, High-Efficacy, and Low-Toxic Cancer Therapy

2018 ◽  
Vol 30 (30) ◽  
pp. 1704490 ◽  
Author(s):  
Xiaobo Jia ◽  
Yihua Zhang ◽  
Yu Zou ◽  
Yao Wang ◽  
Dechao Niu ◽  
...  
Keyword(s):  
Cancer Therapy ◽  
High Efficacy ◽  
Redox Enzyme ◽  
Low Toxic

scholarly journals Cancer Therapy: Dual Intratumoral Redox/Enzyme-Responsive NO-Releasing Nanomedicine for the Specific, High-Efficacy, and Low-Toxic Cancer Therapy (Adv. Mater. 30/2018)

2018 ◽  
Vol 30 (30) ◽  
pp. 1870217 ◽  
Author(s):  
Xiaobo Jia ◽  
Yihua Zhang ◽  
Yu Zou ◽  
Yao Wang ◽  
Dechao Niu ◽  
...  
Keyword(s):  
Cancer Therapy ◽  
High Efficacy ◽  
Redox Enzyme ◽  
Low Toxic

An NRP1/MDM2‐Targeted D‐Peptide Supramolecular Nanomedicine for High‐Efficacy and Low‐Toxic Liver Cancer Therapy

2021 ◽  
pp. 2002197
Author(s):  
Yunjiang Zhou ◽  
Yaxin Chen ◽  
Yingying Tan ◽  
Rong Hu ◽  
Miao‐Miao Niu
Keyword(s):  
Cancer Therapy ◽  
Liver Cancer ◽  
High Efficacy ◽  
Low Toxic

scholarly journals A Self-Assembling Amphiphilic Peptide Dendrimer-Based Drug Delivery System for Cancer Therapy

Pharmaceutics ◽  
2021 ◽  
Vol 13 (7) ◽  
pp. 1092
Author(s):  
Dandan Zhu ◽  
Huanle Zhang ◽  
Yuanzheng Huang ◽  
Baoping Lian ◽  
Chi Ma ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Drug Delivery ◽  
Drug Resistance ◽  
Cancer Therapy ◽  
Self Assembly ◽  
Cancer Drug ◽  
Acquired Drug Resistance ◽  
Self Assembling ◽  
Amphiphilic Peptide ◽  
Peptide Dendrimer

Despite being a mainstay of clinical cancer treatment, chemotherapy is limited by its severe side effects and inherent or acquired drug resistance. Nanotechnology-based drug-delivery systems are widely expected to bring new hope for cancer therapy. These systems exploit the ability of nanomaterials to accumulate and deliver anticancer drugs at the tumor site via the enhanced permeability and retention effect. Here, we established a novel drug-delivery nanosystem based on amphiphilic peptide dendrimers (AmPDs) composed of a hydrophobic alkyl chain and a hydrophilic polylysine dendron with different generations (AmPD KK2 and AmPD KK2K4). These AmPDs assembled into nanoassemblies for efficient encapsulation of the anti-cancer drug doxorubicin (DOX). The AmPDs/DOX nanoformulations improved the intracellular uptake and accumulation of DOX in drug-resistant breast cancer cells and increased permeation in 3D multicellular tumor spheroids in comparison with free DOX. Thus, they exerted effective anticancer activity while circumventing drug resistance in 2D and 3D breast cancer models. Interestingly, AmPD KK2 bearing a smaller peptide dendron encapsulated DOX to form more stable nanoparticles than AmPD KK2K4 bearing a larger peptide dendron, resulting in better cellular uptake, penetration, and anti-proliferative activity. This may be because AmPD KK2 maintains a better balance between hydrophobicity and hydrophilicity to achieve optimal self-assembly, thereby facilitating more stable drug encapsulation and efficient drug release. Together, our study provides a promising perspective on the design of the safe and efficient cancer drug-delivery nanosystems based on the self-assembling amphiphilic peptide dendrimer.

Tandem Molecular Self-assembly for Selective Lung Cancer Therapy with Two Orders of Magnitude Increase in Efficiency

Nanoscale ◽  
2021 ◽  
Author(s):  
Debin Zheng ◽  
Jingfei Liu ◽  
Yinghao Ding ◽  
Limin Xie ◽  
Yingying Zhang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Therapy ◽  
Anticancer Drugs ◽  
Self Assembly ◽  
Therapeutic Efficacy ◽  
Self Assembling ◽  
Lung Cancer Therapy ◽  
Magnitude Increase

In situ self-assembling of prodrug molecules into nanomedicine can elevate the therapeutic efficacy of anticancer medications by enhancing the targeting and enrichment of anticancer drugs at tumor sites. However, the...

scholarly journals Mitochondria-Targeted Self-Assembly of Peptide-Based Nanomaterials

2021 ◽  
Vol 9 ◽  
Author(s):  
Zhen Luo ◽  
Yujuan Gao ◽  
Zhongyu Duan ◽  
Yu Yi ◽  
Hao Wang
Keyword(s):  
Clinical Trials ◽  
Cancer Therapy ◽  
Self Assembly ◽  
Recent Progress ◽  
Assembly Systems ◽  
Targeted Cancer Therapy ◽  
Cancer Treatments ◽  
Self Assembling ◽  
Stimuli Response

Mitochondria are well known to serve as the powerhouse for cells and also the initiator for some vital signaling pathways. A variety of diseases are discovered to be associated with the abnormalities of mitochondria, including cancers. Thus, targeting mitochondria and their metabolisms are recognized to be promising for cancer therapy. In recent years, great efforts have been devoted to developing mitochondria-targeted pharmaceuticals, including small molecular drugs, peptides, proteins, and genes, with several molecular drugs and peptides enrolled in clinical trials. Along with the advances of nanotechnology, self-assembled peptide-nanomaterials that integrate the biomarker-targeting, stimuli-response, self-assembly, and therapeutic effect, have been attracted increasing interest in the fields of biotechnology and nanomedicine. Particularly, in situ mitochondria-targeted self-assembling peptides that can assemble on the surface or inside mitochondria have opened another dimension for the mitochondria-targeted cancer therapy. Here, we highlight the recent progress of mitochondria-targeted peptide-nanomaterials, especially those in situ self-assembly systems in mitochondria, and their applications in cancer treatments.

Sign in / Sign up

Export Citation Format

Share Document